Literature DB >> 17721999

Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.

Melissa A Merritt1, Adèle C Green, Christina M Nagle, Penelope M Webb.   

Abstract

Chronic inflammation has been proposed as the possible causal mechanism that explains the observed association between certain risk factors, such as the use of talcum powder (talc) in the pelvic region and epithelial ovarian cancer. To address this issue we evaluated the potential role of chronic local ovarian inflammation in the development of the major subtypes of epithelial ovarian cancer. Factors potentially linked to ovarian inflammation were examined in an Australia-wide case-control study comprising 1,576 women with invasive and low malignant potential (LMP) ovarian tumours and 1,509 population-based controls. We confirmed a statistically significant increase in ovarian cancer risk associated with use of talc in the pelvic region (adjusted odds ratio 1.17, 95% CI: 1.01-1.36) that was strongest for the serous and endometrioid subtypes although the latter was not statistically significant (adjusted odds ratios 1.21, 95% CI 1.03-1.44 and 1.18, 95% CI 0.81-1.70, respectively). Other factors potentially associated with ovarian inflammation (pelvic inflammatory disease, human papilloma virus infection and mumps) were not associated with risk but, like others, we found an increased risk of endometrioid and clear cell ovarian cancer only among women with a history of endometriosis. Regular use of aspirin and other nonsteroidal anti-inflammatory drugs was inversely associated with risk of LMP mucinous ovarian tumours only. We conclude that on balance chronic inflammation does not play a major role in the development of ovarian cancer. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17721999     DOI: 10.1002/ijc.23017

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  95 in total

1.  Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort.

Authors:  Veronica Wendy Setiawan; Rayna K Matsuno; Galina Lurie; Lynne R Wilkens; Michael E Carney; Brian E Henderson; Laurence N Kolonel; Marc T Goodman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-04       Impact factor: 4.254

2.  Genital powder exposure and the risk of epithelial ovarian cancer.

Authors:  Karin A Rosenblatt; Noel S Weiss; Kara L Cushing-Haugen; Kristine G Wicklund; Mary Anne Rossing
Journal:  Cancer Causes Control       Date:  2011-03-10       Impact factor: 2.506

3.  Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.

Authors:  Xiaojian Ni; Jingjing Ma; Yingchun Zhao; Ying Wang; Shui Wang
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 4.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

Review 5.  Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis.

Authors:  Christina M Nagle; Catherine M Olsen; Torukiri I Ibiebele; Amanda B Spurdle; Penelope M Webb
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

Review 6.  Endometriosis: a high-risk population for major chronic diseases?

Authors:  Marina Kvaskoff; Fan Mu; Kathryn L Terry; Holly R Harris; Elizabeth M Poole; Leslie Farland; Stacey A Missmer
Journal:  Hum Reprod Update       Date:  2015-03-11       Impact factor: 15.610

7.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 8.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 9.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

10.  Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Authors:  Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb
Journal:  Eur J Epidemiol       Date:  2020-09-21       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.